Clinical value of peripheral blood CD62P and CA153 in diagnosis of breast cancer

Abstract

Objective To study the expression of CD62P and carbohydrate antigen 153 (CA153) in peripheral blood of patients with breast cancer, and to explore the value of CD62P and CA153 in the diagnosis of breast cancer. Methods The CD62P ratio in peripheral blood of 60 patients with breast cancer (breast cancer group), 52 patients with breast fibroma (fibroma group) and 25 healthy volunteers (control group) was detected by flow cytometry (FCM). The serum CA153 level was detected by electro chemiluminescence (ECLIA), and the relationship between their expression levels and clinicopathological factors of breast cancer patients was analyzed. The sensitivity and specificity of serum CD62P, CA153 and their combination in the diagnosis of breast cancer were analyzed by receiver operating characteristic (ROC) curve. Results ⑴ The expression levels of CD62P and CA153 in breast cancer group were significantly higher than those in fibroma group and control group (P 0.05). ⑵ The expression levels of CA153 and CD62P in peripheral blood of breast cancer group were correlated with clinical stage and lymphatic metastasis (all P<0.05), and the expression levels of CA153 and CD62P were positively correlated (r=0.514, P<0.05). ⑶ The sensitivity and specificity of combined detection of CD62P and CA153 for breast cancer were higher than those of single detection. Conclusions CD62P is highly expressed in peripheral blood of patients with breast cancer, which may be a new marker for the diagnosis of breast cancer. Key words: Breast neoplasms; Flow cytometry; P-selectin; Antigens, neoplasm